TGF-β/Smad

ALK2-IN-6 is a selective inhibitor of ALK2, exhibiting an IC50 value of 9 nM. This compound is instrumental in investigating the biological role of ALK2 in various contexts, particularly in the study of diffuse intrinsic pontine glioma. Researchers may utilize ALK2-IN-6 to explore its therapeutic potential and molecular mechanisms associated with ALK2 signaling pathways.

TGFβ-IN-1 is a selective inhibitor of the transforming growth factor-β (TGF-β) receptor, targeting the TGF-β signaling pathway. This compound exhibits potent antitumor activity by suppressing tumor growth and metastasis. TGFβ-IN-1 is utilized in cancer research to investigate the molecular mechanisms underlying tumor progression and to explore potential therapeutic strategies for TGF-β-related malignancies.

TJN-331 is a potent, orally active inhibitor of TGF-β1, targeting the TGF-β signaling pathway. This compound demonstrates significant therapeutic potential by ameliorating anti-glomerular basement membrane nephritis in rat models, reducing extracapillary proliferation in glomeruli. Additionally, TJN-331 inhibits mesangial expansion in experimental IgA nephropathy in ddY mice, making it a valuable tool for researching nephritis and IgA nephropathy.

ALK5-IN-6 is a selective inhibitor of ALK5, a key component in the TGF-β signaling pathway. This compound effectively modulates the biological activities of TGF-β, which is crucial for regulating cell proliferation, differentiation, and apoptosis. ALK5-IN-6 is valuable for research into TGF-β-related conditions, including various tumors, fibrotic diseases, inflammatory responses, and autoimmune disorders.

TGFβRI-IN-4 is a potent and orally bioavailable inhibitor of the TGF-β receptor type I (TGFβRI), demonstrating IC50 values of 44 nM and 42.5 nM against ALK5 and NIH3T3 cell lines, respectively. This compound effectively inhibits TGF-β signaling, leading to suppression of tumor growth and reduction in tumor weight in xenograft models. TGFβRI-IN-4 is particularly valuable for research into cancer biology and therapeutic interventions targeting the TGF-β pathway.

HCTZ-CH2-HCTZ is an isomer of hydrochlorothiazide (HCTZ), a thiazide-class diuretic that functions primarily by inhibiting the transforming growth factor-beta (TGF-β)/Smad signaling pathway. This compound exhibits biological activity pertinent to fluid regulation and vascular integrity, making it valuable in research applications focused on cardiovascular biology and renal function. Its unique structure may provide insights into the mechanism of action and therapeutic potential of diuretics in various pathological conditions.

CDD-1281 is a potent and selective inhibitor of the BMPR2 kinase, demonstrating an IC50 value of 1.2 nM. This compound effectively inhibits BMP-mediated gene expression, making it valuable for research applications focused on BMP signaling pathways and their implications in various biological processes.

ALK5-IN-82 is a potent and selective inhibitor of activin receptor-like kinase 5 (ALK5), demonstrating an IC50 value of 9.1 nM. This compound effectively reduces the expression of α-smooth muscle actin, collagen I, and tissue inhibitor of metalloproteinase 1 in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is particularly relevant for the study of cardiac fibrosis and its associated pathways, making it a valuable tool in cardiovascular research applications.

LY550410 is a small-molecule ATP-competitive inhibitor targeting the type I TGF-β receptor kinase. By inhibiting this receptor, LY550410 modulates TGF-β signaling pathways, influencing gene expression and regulating cell growth. This compound is of particular interest for research applications related to cancer biology and therapeutic interventions.

Nicousamide is a potent TGF-β receptor II inhibitor that effectively prevents phosphorylation of this receptor. This compound is instrumental in investigating renal fibrosis and its underlying mechanisms, particularly in animal models of diabetic nephropathy. Researchers can utilize Nicousamide to explore therapeutic strategies aimed at mitigating fibrotic processes in kidney disease.